9-Me-BC is a small synthetic molecule from the beta-carboline family, developed by a German research group at the Technical University of Dresden as a candidate Parkinson’s disease treatment. It is not a peptide. Published research describes it protecting and stimulating dopaminergic neurons and inhibiting monoamine oxidase in cultured cells and rodents, but no human trial of any kind exists, and it inhibits an enzyme, monoamine oxidase, that carries well-known drug-interaction risks that have never been characterised for this specific molecule in people.
Ask about 9-Me-BC
Research snapshot
| Peptide category | Not a peptide: small synthetic molecule, beta-carboline (pyridoindole) family |
| Primary research interest | Dopaminergic neuron protection and regeneration as a candidate Parkinson’s disease treatment |
| Highest available evidence | Published animal and cell-culture (laboratory) evidence only |
| Human research available | No: no registered or published human trial exists |
| Development status | Preclinical research program (German academic group); no clinical development pathway identified |
| Regulatory status | Not approved for human use; no registered human trial |
Technical identity
| Primary name | 9-Me-BC (9-Methyl-beta-carboline) |
| Alternative names | 9-methyl-beta-carboline (full name), 9-Me-beta-C, 9MeBC |
| Peptide sequence | Not applicable: this is a small molecule, not a peptide |
| Amino-acid length | Not applicable |
| Molecular formula | Not independently re-verified in this pass; consult a chemical database directly |
| Molecular weight | Not independently re-verified in this pass |
| CAS Registry Number | Not independently re-verified in this pass |
| PubChem CID | Not independently re-verified in this pass |
| UNII | Not reliably established |
| DrugBank ID | Not listed |
| Chemical modifications | Not applicable in the peptide sense, a methylated beta-carboline small molecule |
| Peptide class | Not a peptide: beta-carboline (pyridoindole) small molecule |
| Primary biological target | Monoamine oxidase A and B (inhibition); reported activity via the organic cation transporter and PI3K signalling pathway in dopaminergic neurons and astrocytes |
| Developer or originator | German academic research group centered at the Technical University of Dresden (Polanski, Gille, Reichmann, and colleagues) |
| Development status | Preclinical (cell culture and rodent studies only) |
What it is
9-Methyl-beta-carboline (9-Me-BC) is a small synthetic molecule in the beta-carboline (pyridoindole) family, developed and studied largely by a German research group centered at the Technical University of Dresden (Polanski, Gille, Reichmann and colleagues). It is not a peptide. Beta-carbolines as a class include both toxic and protective members; 9-Me-BC is specifically studied as a candidate with stimulatory and protective effects on dopaminergic neurons, positioning it as a potential Parkinson’s disease treatment.
Potential benefits and research applications
Dopaminergic neuron protection and regeneration, the central Parkinson’s disease rationale
Published cell-culture and rodent research describes 9-Me-BC increasing tyrosine hydroxylase expression and neurite outgrowth in dopaminergic neurons, the cell type progressively lost in Parkinson’s disease, positioning it as a candidate disease-modifying rather than purely symptomatic treatment.
Evidence: has been shown in cultured cells and rodent models (Tier 3-4, published animal and laboratory evidence); has not been established in any human trial, and none is registered.
Monoamine oxidase inhibition, a mechanism shared with an approved drug class but untested for this molecule in people
9-Me-BC inhibits monoamine oxidase A and B in cell-culture assays, a mechanism shared with approved Parkinson’s and depression medications. This shared mechanism is the basis for interest in the compound, but the drug-interaction risks well known for that mechanism have not been characterised specifically for 9-Me-BC in a human being.
Evidence: is a laboratory/mechanistic finding (Tier 4); has not been established as safe or effective in any human, and no human interaction data exists.
Neurotrophic support via astrocyte stimulation, an additional preclinical mechanism
9-Me-BC has been reported to stimulate astrocytes to express neurotrophic factors including BDNF, proposed as a second, complementary mechanism supporting dopaminergic neuron survival alongside its direct effects on those neurons.
Evidence: is a laboratory/mechanistic finding from cultured cells (Tier 4); has not been established in any living animal’s brain or in any human.
What has actually been tested
Published research describes 9-Me-BC increasing tyrosine hydroxylase expression and neurite outgrowth in dopaminergic neurons, inhibiting monoamine oxidase A and B (with an IC50 of about 1 micromolar for MAO-A and 15.5 micromolar for MAO-B in one cell-culture study), and stimulating astrocytes to express neurotrophic factors including BDNF, through a mechanism reported to run via the organic cation transporter and the PI3K signalling pathway. These findings come from cultured dopaminergic and cortical astrocyte cell lines and from rodent studies; no human trial was located for this entry.
No registered clinical trial of 9-Me-BC, for Parkinson’s disease or any other indication, appears on ClinicalTrials.gov.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate. No human trial of 9-Me-BC exists, so there is no studied human dose to compare a circulating figure against.
| Reported use or research objective | Route reported | Amount reported | Frequency reported | Reported duration | Evidence or source category |
|---|---|---|---|---|---|
| Dopaminergic neuron protection / MAO inhibition (cell culture) | In vitro (cultured dopaminergic neurons, cortical astrocytes) | MAO-A IC50 ≈1 micromolar; MAO-B IC50 ≈15.5 micromolar (one cell-culture study) | Not applicable (assay concentration, not a dosing schedule) | Not applicable | Published laboratory research (Keller et al., 2020) |
| Dopaminergic neuron protection and regeneration (rodent studies) | Not specified for human translation | Not independently re-extracted for this page | Not specified | Not specified | Published animal research (Polanski et al., 2011 review) |
| Neuroprotective/dopaminergic support, general (community/vendor use) | Oral | Varies by listing | Varies by listing | Varies by listing | Community/vendor reported: no published animal or human dose-response study behind any specific figure |
What is not known
Whether 9-Me-BC’s dopaminergic-neuron-protective and MAO-inhibiting effects, established in cell culture and rodent models, reproduce in a human being with Parkinson’s disease or any other condition. No human trial exists.
Human pharmacokinetics, human dosing, and human safety, including interactions relevant to a compound that inhibits monoamine oxidase, a drug class with well-known interaction risks (notably with other serotonergic or dopaminergic agents) that has not been characterised for this specific molecule in people.
Whether 9-Me-BC’s reported benefits can be separated from the toxic effects associated with other members of the beta-carboline family it belongs to.
Frequently asked questions
What is 9-Me-BC?
9-Me-BC (9-methyl-beta-carboline) is a small synthetic molecule from the beta-carboline family, studied in Germany as a candidate Parkinson’s disease treatment. It is not a peptide.
How does 9-Me-BC work?
It is reported to protect and stimulate dopaminergic neurons, inhibit monoamine oxidase A and B, and stimulate astrocytes to release neurotrophic factors, through a mechanism reported to run via the organic cation transporter and the PI3K signalling pathway. All of this is cell-culture and rodent data.
What dosage has been studied?
No established or reliably sourced human dosing information was identified. No human trial of 9-Me-BC exists.
What dosage commonly circulates online?
Circulating listings describe oral capsule or powder use at doses that vary by seller, with no published animal or human dose-response study behind any specific figure.
Has 9-Me-BC been studied in humans?
No. No registered clinical trial of 9-Me-BC, for Parkinson’s disease or any other indication, appears on ClinicalTrials.gov, and no human trial was located anywhere else for this entry.
Is 9-Me-BC approved for use?
No. It is not approved for human use in any jurisdiction and has no registered human trial.
What routes of administration are reported?
Circulating material describes oral use. Published research does not report a route relevant to human dosing, since it is limited to cultured cells and rodents.
Is 9-Me-BC safe to combine with other medications?
This has not been established. It inhibits monoamine oxidase, an enzyme target with well-known interaction risks, particularly with other serotonergic or dopaminergic agents, that have not been characterised for this specific molecule in a human being.
What side effects have been reported?
No human safety or adverse-event data exists, because no human trial of 9-Me-BC has been conducted. Its membership in the beta-carboline family, which includes both toxic and protective members, is a specific unresolved concern.
What remains unknown about 9-Me-BC?
Whether its dopaminergic-neuron-protective effects reproduce in a human being; its human pharmacokinetics, dosing, safety and drug-interaction profile, none of which exist; and whether its benefits can be separated from the toxicity of other beta-carbolines.
Bottom line
9-Me-BC is a coherent, German-led research program built around a real and specific idea, protecting dopaminergic neurons in Parkinson’s disease, but it remains entirely preclinical. Every finding is from cultured cells or rodents, no human trial has ever been registered, and the compound’s monoamine-oxidase-inhibiting mechanism carries drug-interaction risks that have simply never been tested in a human being.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| Neuroprotective/dopaminergic support, general | Oral | Varies by listing | Varies by listing | Varies by listing |
Circulating listings for 9-Me-BC describe oral capsule or powder use at doses that vary by seller. There is no human trial of any kind to check that figure against; the published research for this compound is limited to cultured cells and rodents, none of which reported a dose in a form comparable to a per-capsule human figure.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Sources
- Polanski W, Reichmann H, Gille G. Stimulation, protection and regeneration of dopaminergic neurons by 9-methyl-beta-carboline: a new anti-Parkinson drug? Expert Rev Neurother 2011;11(6):845-60. Review, cell culture and rodent data only. PMID 21651332
- Keller S, et al. 9-Methyl-beta-carboline inhibits monoamine oxidase activity and stimulates the expression of neurotrophic factors by astrocytes. J Neural Transm (Vienna) 2020;127(7):999-1012. Cultured cell study, MAO-A/B IC50 values, rodent-derived astrocytes. PMID 32285253
Compare 9-ME-BC with related compounds
Research area: Neuro and cognitive.